

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in this application.

Listing of Claims:

Claims 1 –60. Cancelled.

61 (New). An orally administrable pantoprazole multiparticulate composition, wherein the multiparticulates comprise pantoprazole sodium and wherein following administration to humans the composition has a mean geometric AUC ratio of pantoprazole of between 88% to 100% (multiparticulates comprising 40 mg pantoprazole to 40 mg commercial pantoprazole tablet) and a Cmax ratio of pantoprazole of between 60% to 74% (multiparticulates comprising 40 mg pantoprazole to 40 mg commercial pantoprazole tablet).

62 (New). The orally adminstrable pantoprazole multiparticulate composition according to claim 61, wherein said pantoprazole sodium is pantoprazole sodium sesquihydrate.

63 (New). The composition according to claim 61, wherein the multiparticulates have an average diameter of about 0.7 to about 1.25 mm.

64 (New). The composition according to claim 61 in an aqueous suspension.

65 (New). The composition according to claim 61 contained in a capsule.

66 (New). The composition according to claim 61, wherein the multiparticulates have spheroid cores comprising a pantoprazole compound present in

an amount of about 40 mg of pantoprazole per 100 mg uncoated multiparticulates, wherein the amount of pantoprazole is measured in the free drug form.

67 (New). The composition according to claim 61, wherein the multiparticulate further comprises an initial seal coat on the spheroid core, an enteric coat on the initial seal coat, and an optional final seal coat.

68 (New). The composition according to claim 67, wherein the spheroid core further comprises a surfactant or a combination of surfactants present in a ratio from about 10:1 to about 5:3 pantoprazole:surfactant(s) (w/w) or from about 2% to about 7% (w/w) of surfactant(s) to core.

69 (New). The composition according to claim 68, wherein the surfactant comprises sodium lauryl sulfate or a polysorbate, or a combination thereof.

70 (New). The composition according to claim 69, wherein the surfactant is polysorbate 80.

71 (New). An orally administrable pantoprazole multiparticulate composition, wherein the multiparticulates comprise pantoprazole sodium, wherein following administration of 40 mg of said pantoprazole multiparticulates sprinkled in applesauce to humans the pantoprazole is characterised by a geometric mean AUC ratio of between 84% to 96% (multiparticulates comprising 40 mg pantoprazole to 40 mg commercial pantoprazole tablet) and a geometric mean C_{max} ratio of between 56% to 70% (multiparticulates comprising 40 mg pantoprazole to 40 mg commercial pantoprazole tablet).

72 (New). The composition according to claim 71, wherein the multiparticulates have a mean diameter of about 0.7 to about 1.25 mm.

73 (New). The composition according to claim 71 in an aqueous suspension.

74 (New). The composition according to claim 71 contained in a capsule.

75 (New). The composition according to claim 71, wherein said multiparticulates have spheroid cores comprising a pantoprazole compound present in an amount of about 40 mg of pantoprazole per 100 mg uncoated multiparticulates, wherein the amount of pantoprazole is measured in the free drug form.

76 (New). The composition according to claim 72, wherein the multiparticulates further comprises an initial seal coat on the spheroid core, an enteric coat on the initial seal coat, and an optional final seal coat.

77 (New). The composition according to claim 75, wherein the spheroid core further comprises a surfactant or a combination of surfactants present in a ratio from about 10:1 to about 5:3 pantoprazole:surfactant(s) (w/w) or from about 2% to about 7% (w/w) of surfactant(s) to core.

78 (New). The composition according to claim 77, wherein the surfactant comprises sodium lauryl sulfate or a polysorbate, or a combination thereof.

79 (New). The composition according to claim 78, wherein the surfactant is polysorbate 80.

80 (New). An orally administrable pantoprazole multiparticulate composition, wherein the multiparticulates comprise pantoprazole sodium and wherein following administration to humans said multiparticulate composition provides a geometric mean AUC of between 5451 to 5629 ng.h/mL and geometric mean C_{max} of between 1865 to 1929 ng/mL.

81 (New). The composition according to claim 80, wherein the multiparticulates have an average diameter of about 0.7 to about 1.25 mm.

82 (New). The composition according to claim 80 in an aqueous suspension.

83 (New). The composition according to claim 80 contained in a capsule.

84 (New). The composition according to claim 80, wherein said multiparticulates have spheroid cores comprising a pantoprazole compound present in an amount of about 40 mg of pantoprazole per 100 mg uncoated multiparticulates, wherein the amount of pantoprazole is measured in the free drug form.

85 (New). The composition according to claim 81, wherein the multiparticulates further comprises an initial seal coat on the spheroid core, an enteric coat on the initial seal coat, and an optional final seal coat.

86 (New). The composition according to claim 85, wherein the spheroid core further comprises a surfactant or a combination of surfactants present in a ratio from about 10:1 to about 5:3 pantoprazole:surfactant(s) (w/w) or from about 2% to about 7% (w/w) of surfactant(s) to core.

87 (New). The composition according to claim 86, wherein the surfactant comprises sodium lauryl sulfate or a polysorbate, or a combination thereof.

88 (New). The composition according to claim 87, wherein the surfactant is polysorbate 80.